PROVIDENCE, R.I.--(BUSINESS WIRE)--May 9, 2007--Amgen (NASDAQ:AMGN) today announced results of voting at the company's Annual Meeting of Stockholders, held at the Westin Providence hotel in Providence, R.I. Approximately 86.9 percent of outstanding shares were represented at the meeting.
The director nominees, Frank J. Biondi, Jr., Jerry D. Choate, Frank C. Herringer and Gilbert S. Omenn, were each reelected to Amgen's Board of Directors, receiving at least 96.5 percent of 'For' votes. With the reelection of these directors, Amgen currently has 10 directors.
With 97.5 percent of 'For' votes, stockholders ratified Ernst & Young as Amgen's independent registered public accountants for the year ending Dec. 31, 2007. Stockholders also approved company-sponsored proposals to amend the company's Restated Certificate of Incorporation and Bylaws to permit the declassification of the Board of Directors. Stockholders holding approximately 98 percent of the company's outstanding shares cast votes in favor of these two proposals, which results in the company's directors being required to stand for reelection each year, beginning with the company's 2008 Annual Meeting of Stockholders.
Stockholders rejected a proposal that would require the company to post an animal welfare policy on its website and issue a report to stockholders tracking the company's adherence to the policy. The proposal received only five percent of 'For' votes. Stockholders also rejected a proposal that would require the company to publish an annual sustainability report disclosing the company's social and environmental practices. The proposal received 9.7 percent of 'For' votes.
Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.
CONTACT: Amgen, Thousand Oaks
David Polk, 805-490-0661 (media)
Kristen Davis, 805-447-3008 (media)
Arvind Sood, 805-447-1060 (investors)